ESMO
The Short-HER trial

three prognostic groups:

low risk
pathologic tumour size < 2cm and N0
37.5% of patients
intermediate risk
pT < 2cm and any N category
51.9%
high risk
pT > 2cm and N4+
10.5%

low and intermediate risk had similar five-year DFS with a nine-week course of trastuzumab (88%) as with one year 89%

hazard ratio 1.02、95%CI 0.78-1.33

risk of cardiac events was nearly three times lower
4.5% vs 12.8%、relative risk 2.88 95% CI 1.85-4.47

Women at low and intermediate risk of relapse accounted for 89% of patients in the study.

Abstract 191PD_PR
9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio

Poster Discussion Session on Saturday 20 October, Annals of Oncology, Volume 29 Supplement 8 October 2018